CORE--TISSUE PROCUREMENT/DC LABORATORY

$104,330P01FY2002DENIH

University Of Pittsburgh At Pittsburgh, Pittsburgh PA

Investigators

Linked publications & trials

Paper 25735641 Paper 21965721 Paper 21856769 Paper 21409596 Paper 20577877 Paper 20352042 Paper 20225066 Paper 19858205 Paper 19296526 Paper 19184003 Paper 19155494 Paper 19073006 Paper 18767952 Paper 18559587 Paper 18429494 Paper 18292519 Paper 18221909 Paper 18157016 Paper 18045068 Paper 17975141 Paper 17974998 Paper 17942609 Paper 17875728 Paper 17691114 Paper 17690565 Paper 17631051 Paper 17617419 Paper 17294448 Paper 17265021 Paper 17190648 Paper 17182569 Paper 17111427 Paper 17103408 Paper 17082593 Paper 16998881 Paper 16888780 Paper 16818683 Paper 16331601 Paper 16284959 Paper 16278415 Paper 16032397 Paper 15959774 Paper 15925829 Paper 15889251 Paper 15814633 Paper 15785875 Paper 15714205 Paper 15709166 Paper 15608425 Paper 15356097 Paper 15297413 Paper 15265880 Paper 15118842 Paper 12858347 Paper 12850486 Paper 12839958 Paper 12827303 Paper 12747748 Paper 12594840 Paper 12592313 Paper 12576430 Paper 12569601 Paper 12537666 Paper 12395923 Paper 12374681 Paper 12171883 Paper 12080146 Paper 12067999 Paper 12060618 Paper 11870501 Paper 11801674 Paper 11696597 Paper 11696596 Paper 11447222 Paper 11265774 Paper 11156370 Paper 11084618 Paper 11067956 Paper 11063743 Paper 10910067 Paper 10831322 Paper 10778963 Paper 10766165 Paper 10733772 Paper 10732775 Paper 10706869 Paper 10702485

Abstract

DESCRIPTION: (provided by applicant) Core B will consist of two components: the Tissue Procurement Facility and Dendritic Cell (DC) Laboratory. They will provide support to all four projects in this program. The former will procure, process, and distribute or store specimens from patients with oral carcinoma or control individuals, e.g., non-cancer patients undergoing uvulopalatopharyngoplasty or tonsillectomy. Specimens, including tumor biopsies, normal mucosal tissues, tissues adjacent to tumors, and peripheral blood mononuclear cells (PBMC) will be collected from patients or controls processed by trained personnel in accordance with the established SOP and under rigorous quality control measures. Specimens will be triaged according to the protocol established with the participating investigators and will be accompanied by histopathologic diagnoses and clinical/demographic data. Core B will handle fresh or cryopreserved specimens, microdissect tissues and prepare RNA or DNA as needed. The DC laboratory will generate human DC from PBMC precursors and culture them in the presence of IL-4 and GM-CSF in preparation for in vitro sensitization experiments. The laboratory, which operates according to FDA-approved GLP guidelines, will also grow DC for administration to patients on vaccination protocols. DC will be tested for phenotype and antigen-presenting functions prior to their use in priming assays with autologous T cells. Core B will be responsible for the quality and safely of cellular products administered to patients with OSCC. Cytokine assays and p53 antibody determinations will also be performed by the Core. Monitoring of patients receiving the antitumor vaccine for the frequency of T cells responding to individual peptides and to OSCC targets will be performed using ELISPOT and tetramer-based assays. Services of Core B are perceived as essential for the development of a strong vaccination grogram.

View original record on NIH RePORTER →